Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798260 | 0.93 | SLC29A1 (0.50) | SLC29A1ADORA3ADORA2AADORA2B | |
| SCHEMBL1796277 | 0.88 | ADORA3 (0.52) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL1798638 | 0.84 | SLC29A1 (0.54) | SLC29A1ADORA1ADORA3ADORA2A | |
| SCHEMBL1797623 | 0.84 | SLC29A1 (0.52) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL1798642 | 0.80 | UBA6 (0.58) | SLC29A1ADORA1ADORA3 | |
| SCHEMBL1796397 | 0.79 | ADORA3 (0.51) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL1796387 | 0.79 | ADORA3 (0.48) | SLC29A1ADORA1ADORA3ADORA2A | |
| SCHEMBL1796046 | 0.78 | SLC29A1 (0.57) | SLC29A1ADORA3 | |
| SCHEMBL1797176 | 0.78 | ADORA3 (0.67) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL1798256 | 0.77 | SLC29A1 (0.55) | SLC29A1ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | SLC29A1 1761/4885ADORA1 857/4885DOT1L 2827/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | SLC29A1 3671/4885ADORA1 2055/4885DOT1L 3312/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | SLC29A1 1134/4885ADORA1 232/4885DOT1L 3408/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | SLC29A1 3671/4885ADORA1 2055/4885DOT1L 3312/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | SLC29A1 1134/4885ADORA1 232/4885DOT1L 3408/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | SLC29A1 3671/4885ADORA1 2055/4885DOT1L 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.